Search
Now showing items 1-10 of 11
Inhibition of GSK-3 beta activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in breast cancer
(International Journal of Molecular Medicine, 2014)
Targeting signaling pathways in prostate cancer
(International Journal of Molecular Medicine, 2012)
Role of NGAL (Lcn2) in prostate cancer invasion
(International Journal of Molecular Medicine, 2012)
NO-hybridized protease inhibitors as a new class of anticancer compounds. Saquinavir-NO as prototypical example?
(International Journal of Molecular Medicine, 2012)
Suppressing prostate cancer by targeting NGAL
(International Journal of Molecular Medicine, 2014)
Generation of new anti-cancer compounds from Nitric Oxide (NO)-hybridization of protease inhibitors. Saquinavir-NO as prototypic example?
(International Journal of Molecular Medicine, 2010)
Novel approaches to target the prostate cancer stem cell - eliminating the root of the cancer
(International Journal of Molecular Medicine, 2011)
Anti-melanoma potential of nitric oxide-modified form of HIV inhibitor- saquinavir; cell specific mode of drug action
(International Journal of Molecular Medicine, 2010)
The effects of the nitric oxide-modified HIV protease inhibitor Saquinavir-NO (Saq-NO) on p53-deficient androgen independent prostate cancer cell lines
(International Journal of Molecular Medicine, 2010)
Sensitization of cancer stem cells based on inhibiting key signal transduction pathways
(International Journal of Molecular Medicine, 2011)